WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 204430
CAS#: 1095253-39-6
Description: ARQ-621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division. Over-expression of Eg5 causes genomic instability and tumor formation in mice; therefore, Eg5 is a potential anti-cancer target. Preclinical data shows anti-tumor activity of ARQ 621 across a wide range of cell lines from human solid and hematological malignancies.
MedKoo Cat#: 204430
Name: ARQ-621
CAS#: 1095253-39-6
Chemical Formula: C28H24Cl2FN5O2
Exact Mass: 551.12911
Molecular Weight: 552.42686
Elemental Analysis: C, 60.88; H, 4.38; Cl, 12.84; F, 3.44; N, 12.68; O, 5.79
Synonym: ARQ621; ARQ 621; ARQ-621.
IUPAC/Chemical Name: (R)-N-(3-aminopropyl)-3-chloro-N-(1-(7-chloro-4-oxo-3-(phenylamino)-3,4-dihydroquinazolin-2-yl)but-3-yn-1-yl)-2-fluorobenzamide
InChi Key: UPJSUQWHUVLLNW-XMMPIXPASA-N
InChi Code: InChI=1S/C28H24Cl2FN5O2/c1-2-8-24(35(16-7-15-32)27(37)21-11-6-12-22(30)25(21)31)26-33-23-17-18(29)13-14-20(23)28(38)36(26)34-19-9-4-3-5-10-19/h1,3-6,9-14,17,24,34H,7-8,15-16,32H2/t24-/m1/s1
SMILES Code: O=C(N(CCCN)[C@@H](C(N1NC2=CC=CC=C2)=NC3=C(C=CC(Cl)=C3)C1=O)CC#C)C4=CC=CC(Cl)=C4F
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 552.42686 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Rath O, Kozielski F. Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39. doi: 10.1038/nrc3310. Review. PubMed PMID: 22825217.
